Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB

Neuroscience. 2007 Jan 5;144(1):198-207. doi: 10.1016/j.neuroscience.2006.09.001. Epub 2006 Oct 19.


In this study, we have used 6-hydroxydopamine-lesioned rats to examine changes in striatal junD and fosB/deltafosB expression induced by acute and chronic treatment with L-DOPA (5 and 15 days). Changes at the protein levels were studied using Western immunoblotting while mRNA changes were compared using in situ hybridization histochemistry. We observed a significant increase in the level of deltaFosB proteins after chronic treatment with L-DOPA, an effect that was not observed for JunD proteins. In addition, the upregulation of deltaFosB was already present after an acute treatment but increased upon chronic treatment. By contrast, junD and deltafosB mRNA were both upregulated significantly above control levels after an acute injection of L-DOPA. In conclusion, this study suggests a differential expression pattern of junD and deltafosB in a rat model of L-DOPA-induced dyskinesia. The upregulation of deltaFosB protein, but not JunD, is likely to reflect an increased stability of the deltaFosB proteins without ongoing enhanced transcription of the encoding genes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology*
  • Blotting, Western
  • Denervation
  • Female
  • Gene Expression Regulation / drug effects
  • Immunohistochemistry
  • In Situ Hybridization
  • Levodopa / pharmacology*
  • Neostriatum / drug effects
  • Neostriatum / metabolism
  • Oxidopamine / toxicity
  • Proto-Oncogene Proteins c-fos / biosynthesis*
  • Proto-Oncogene Proteins c-jun / biosynthesis*
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • Rats
  • Rats, Sprague-Dawley


  • Antiparkinson Agents
  • Fosb protein, rat
  • Proto-Oncogene Proteins c-fos
  • Proto-Oncogene Proteins c-jun
  • RNA, Messenger
  • Levodopa
  • Oxidopamine